Digipath
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

I think you are absolutely correct.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Pwrinv Member Profile
 
Followed By 0
Posts 74
Boards Moderated 0
Alias Born 03/16/12
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2019 4:43:20 PM
Amarin Provides Preliminary 2018 Results and 2019 Outlook GlobeNewswire Inc. - 1/4/2019 4:15:00 PM
Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 GlobeNewswire Inc. - 1/2/2019 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:35:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/29/2018 4:08:05 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 11/29/2018 3:07:20 PM
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference GlobeNewswire Inc. - 11/28/2018 6:25:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/28/2018 5:24:09 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 8:59:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/26/2018 5:32:33 PM
Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 4:23:58 PM
Amarin to Present at the Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/20/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/14/2018 6:03:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 6:18:24 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... PR Newswire (US) - 11/11/2018 10:32:00 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... GlobeNewswire Inc. - 11/10/2018 3:00:00 PM
Amarin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire Inc. - 11/8/2018 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2018 4:13:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/1/2018 7:06:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/1/2018 7:05:12 AM
Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/1/2018 5:00:00 AM
Amarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions ... GlobeNewswire Inc. - 10/26/2018 5:00:00 AM
Pwrinv   Saturday, 01/12/19 09:52:02 AM
Re: rafunrafun post# 171871
Post # of 172909 
I think you are absolutely correct.

Another misconception is that BP will pay now for what Vascepa sales might be in the future....BP will pay for what they believe they could get Vascepa sales to after discounting NPV, market risks, regulatory risk and economic risks.... Other unproven indications will be significantly discounted because of all the above risks, and they are unproven. $100 today is unrealistic.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist